Observational Study of viability of the clinical sequencing for AML (JALSG CS-17-CSeq)

Not Applicable

• Conditions: AML(acute myeloid leukemia)

• Registration Number: JPRN-UMIN000031343
• Lead Sponsor: Japan Adult Leukemia Study Group

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-02-19
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

(1)APL with PML-RARA, Myeloid sarcoma (2) Less than 30% of blast and meet the RAEB-t in the FAB classification. (3)Patients with complications including an activity double cancer, uncontrolled diabetes, and a serious infection.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification rate of patients with potentially actionable findings(PAF) by introduction of the clinical sequencing.

Secondary Outcome Measures

Name	Time	Method
Identification rate of the clinically impactful findings (CIF). The average number of days required to return the genome analysis information to the doctor in charge. Identification rate of patients in which the genome cannot be analyzed and its causes. Identification rate of patients that germ cell sequence mutations were identified which are supposed to return the information report.